Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (42)
Meng-Lan Luo, Qian Zhao, Xiang-Hong He, Xin Xie, Hong-Ping Zhu, Feng-Ming You, Cheng Peng, Gu Zhan & Wei Huang. (2023) Research progress of indole-fused derivatives as allosteric modulators: Opportunities for drug development. Biomedicine & Pharmacotherapy 162, pages 114574.
Crossref
Crossref
Maria Pérez-Peiró, Paula Valentí-Serra, Blanca León-González, Coral Ampurdanés, Xavier Duran, José Yélamos & Esther Barreiro. (2023) Attenuation of Tumor Burden in Response to Rucaparib in Lung Adenocarcinoma: The Contribution of Oxidative Stress, Apoptosis, and DNA Damage. International Journal of Molecular Sciences 24:3, pages 2580.
Crossref
Crossref
Hongyu Qin, Jian Zhang, Yilu Zhao, Lihui Zhang, Jinhong Feng & Lei Zhang. (2023) Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer. Frontiers in Pharmacology 13.
Crossref
Crossref
Aashish Soni, Xixi Lin, Emil Mladenov, Veronika Mladenova, Martin Stuschke & George Iliakis. (2022) BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy. Cancers 14:22, pages 5619.
Crossref
Crossref
Silvia Schmidtova, Natalia Udvorkova, Zuzana Cierna, Samuel Horak, Katarina Kalavska, Michal Chovanec, Lucia Rojikova, Miriam Vulevova, Lucia Kucerova & Michal Mego. (2022) Effect of the PARP inhibitor veliparib on germ cell tumor cell lines. Oncology Letters 24:5.
Crossref
Crossref
Mohammad M. Al-Sanea, Garri Chilingaryan, Narek Abelyan, Michael Mamikonyan, Hayk Gasparyan, Sargis Hovhannisyan, Abdelrahman Hamdi, Ahmed R. Ali, Samy Selim & Ahmed A. B. Mohamed. (2022) Combination of ligand and structure based virtual screening approaches for the discovery of potential PARP1 inhibitors. PLOS ONE 17:9, pages e0272065.
Crossref
Crossref
Xianhai Huang & David Yu‐Kai Chen. 2022. Contemporary Accounts in Drug Discovery and Development. Contemporary Accounts in Drug Discovery and Development
341
384
.
Yusuke Sumimoto, Shinya Okawa, Tomoya Inoue, Kazufumi Masuda, Masato Maruyama & Kazutaka Higaki. (2022) Extensive improvement of oral bioavailability of mebendazole, a brick dust, by polymer-containing SNEDDS preparation: Disruption of high crystallinity by utilizing its counter ion. European Journal of Pharmaceutics and Biopharmaceutics 172, pages 213-227.
Crossref
Crossref
Gregory D. Bowden, Sophie Stotz, Johannes Kinzler, Christian Geibel, Michael Lämmerhofer, Bernd J. Pichler & Andreas Maurer. (2021)
DoE Optimization Empowers the Automated Preparation of Enantiomerically Pure [
18
F]Talazoparib and its
In Vivo
Evaluation as a PARP Radiotracer
. Journal of Medicinal Chemistry 64:21, pages 15690-15701.
Crossref
Crossref
Ruixue Huang & Ping-Kun Zhou. (2021) DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduction and Targeted Therapy 6:1.
Crossref
Crossref
Lei Zhong, Yueshan Li, Liang Xiong, Wenjing Wang, Ming Wu, Ting Yuan, Wei Yang, Chenyu Tian, Zhuang Miao, Tianqi Wang & Shengyong Yang. (2021) Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduction and Targeted Therapy 6:1.
Crossref
Crossref
Niknam Riyahi, M. Reza Saadatzadeh, Khadijeh Bijangi-Vishehsaraei, Farinaz Barghi, Pankita H. Pandya & Karen E. Pollok. 2021. DNA - Damages and Repair Mechanisms. DNA - Damages and Repair Mechanisms.
Lotte van Beek, Éilís McClay, Saleha Patel, Marianne Schimpl, Laura Spagnolo & Taiana Maia de Oliveira. (2021) PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling. International Journal of Molecular Sciences 22:10, pages 5112.
Crossref
Crossref
Sonali S. Bharate. (2021) Recent developments in pharmaceutical salts: FDA approvals from 2015 to 2019. Drug Discovery Today 26:2, pages 384-398.
Crossref
Crossref
Xiaochen Wu, Qiqi Li, Fan Zhang, Lijun Wang, Jun Wang, Junting Fan, Guohu Di & Chuanlong Guo. (2021) Novel poly (ADP-ribose) polymerases inhibitor DHC-1 exhibits in vitro and in vivo anticancer activity on BRCA-deficient pancreatic cancer cells. Food and Chemical Toxicology 147, pages 111892.
Crossref
Crossref
Christina R. Washington, Debra L. Richardson, Amma F. Agyemang, Kunle O. Odunsi & Kathleen N. Moore. 2021. Overcoming Ovarian Cancer Chemoresistance. Overcoming Ovarian Cancer Chemoresistance
129
149
.
A. Selen Gurkan-Alp, Mehmet Alp, Arzu Z. Karabay, Asli Koc & Erdem Buyukbingol. (2020) Synthesis of Some Benzimidazole-derived Molecules and their Effects on PARP-1 Activity and MDA-MB-231, MDA-MB-436, MDA-MB-468 Breast Cancer Cell Viability. Anti-Cancer Agents in Medicinal Chemistry 20:14, pages 1728-1738.
Crossref
Crossref
Yue Zhao, Liu-Xia Zhang, Ting Jiang, Jing Long, Zhong-Ye Ma, Ai-Ping Lu, Yan Cheng & Dong-Sheng Cao. (2020) The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy–Current progress and future direction. European Journal of Medicinal Chemistry 203, pages 112570.
Crossref
Crossref
Ryan L. Hanson & Eric Batchelor. (2020) Rucaparib Treatment Alters p53 Oscillations in Single Cells to Enhance DNA-Double-Strand-Break-Induced Cell Cycle Arrest. Cell Reports 33:2, pages 108240.
Crossref
Crossref
Maddison Rose, Joshua T. Burgess, Kenneth O’Byrne, Derek J. Richard & Emma Bolderson. (2020) PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Lijun Wang, Shuhong Zhang, Xuemin Yu & Chuanlong Guo. (2020)
Novel Poly(ADP-ribose) Polymerase-1 Inhibitor DDHCB Inhibits Proliferation of BRCA Mutant Breast Cancer Cell
In Vitro
and
In Vivo
through a Synthetic Lethal Mechanism
. Chemical Research in Toxicology 33:7, pages 1874-1881.
Crossref
Crossref
Antonella Pietragalla, Francesca Ciccarone, Camilla Nero, Giovanni Scambia, Domenica Lorusso & Gennaro Daniele. (2020) Integration of PARP-inhibitors in ovarian cancer therapy. Exploration of Targeted Anti-tumor Therapy 1:3, pages 171-182.
Crossref
Crossref
Stefania Cocco, Michela Piezzo, Alessandra Calabrese, Daniela Cianniello, Roberta Caputo, Vincenzo Di Lauro, Giuseppina Fusco, Germira di Gioia, Marina Licenziato & Michelino de Laurentiis. (2020) Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. International Journal of Molecular Sciences 21:13, pages 4579.
Crossref
Crossref
Sudeep Gupta, Shona Nag, Shyam Aggarwal, Amit Rauthan & Narayanankutty Warrier. (2019) Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives – a review. Journal of Ovarian Research 12:1.
Crossref
Crossref
Christina R Washington, Debra L Richardson & Kathleen N Moore. (2019) Olaparib in the treatment of ovarian cancer. Future Oncology 15:30, pages 3435-3449.
Crossref
Crossref
Mark A Perazella, Biruh Workeneh & Sheldon Chen. (2019) Evolution of the kidney–cancer connection. Journal of Onco-Nephrology 3:2, pages 88-91.
Crossref
Crossref
Alanna M. Cameron, Angela Castoldi, David E. Sanin, Lea J. Flachsmann, Cameron S. Field, Daniel. J. Puleston, Ryan L. Kyle, Annette E. Patterson, Fabian Hässler, Joerg M. Buescher, Beth Kelly, Erika L. Pearce & Edward J. Pearce. (2019) Inflammatory macrophage dependence on NAD+ salvage is a consequence of reactive oxygen species–mediated DNA damage. Nature Immunology 20:4, pages 420-432.
Crossref
Crossref
Wei Qin, Hong-Jie Wu, Lu-Qi Cao, Hui-Jin Li, Chun-Xia He, Dong Zhao, Lu Xing, Peng-Quan Li, Xi Jin & Hui-Ling Cao. (2019) Research Progress on PARP14 as a Drug Target. Frontiers in Pharmacology 10.
Crossref
Crossref
Christina Washington, Camille C. Gunderson & Kathleen N. Moore. (2019) Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research. Current Opinion in Obstetrics & Gynecology 31:1, pages 4-11.
Crossref
Crossref
Robert L Coleman & Jonathan A Ledermann. (2019) Maintenance Treatment for Recurrent Ovarian Carcinoma – Evidence Supporting the Efficacy and Safety of PARP Inhibitors. European Oncology & Haematology 15:1, pages 29.
Crossref
Crossref
Abdel B. Halim. 2019. Biomarkers, Diagnostics and Precision Medicine in the Drug Industry. Biomarkers, Diagnostics and Precision Medicine in the Drug Industry
11
40
.
Nicola Maurea, Rolando Paciello, Carmela Coppola & Dimitrios Farmakis. 2019. Cardiovascular Complications in Cancer Therapy. Cardiovascular Complications in Cancer Therapy
123
132
.
Samantha Chao & Bora Lim. 2019. International Manual of Oncology Practice. International Manual of Oncology Practice
991
1006
.
Mohamad El Amki, Dominique Lerouet, Marie Garraud, Fei Teng, Virginie Beray-Berthat, Bérard Coqueran, Benoît Barsacq, Charlotte Abbou, Bruno Palmier, Catherine Marchand-Leroux & Isabelle Margaill. (2018) Improved Reperfusion and Vasculoprotection by the Poly(ADP-Ribose)Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice. Molecular Neurobiology 55:12, pages 9156-9168.
Crossref
Crossref
Dong Li, Jingyan Yang, Huanzhi Ma, Chengliang Sun & Rongjie Feng. (2018)
Retracted
: Inositol polyphosphate‐4‐phosphatase type II and rucaparib treatment inhibit the growth of osteosarcoma cells dependent on phosphoinositide 3‐kinase/protein kinase B pathway
. Journal of Cellular Biochemistry 119:12, pages 9899-9909.
Crossref
Crossref
Magdalena Koczkowska, Natalia Krawczynska, Maciej Stukan, Alina Kuzniacka, Izabela Brozek, Marcin Sniadecki, Jaroslaw Debniak, Dariusz Wydra, Wojciech Biernat, Piotr Kozlowski, Janusz Limon, Bartosz Wasag & Magdalena Ratajska. (2018) Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients. Cancers 10:11, pages 442.
Crossref
Crossref
Angela Musella, Erlisa Bardhi, Claudia Marchetti, Laura Vertechy, Giusy Santangelo, Carolina Sassu, Federica Tomao, Francesco Rech, Renzo D'Amelio, Marco Monti, Innocenza Palaia, Ludovico Muzii & Pierluigi Benedetti Panici. (2018) Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer. Cancer Treatment Reviews 66, pages 7-14.
Crossref
Crossref
Alicia J. Angelbello, Jonathan L. Chen, Jessica L. Childs-Disney, Peiyuan Zhang, Zi-Fu Wang & Matthew D. Disney. (2018) Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. Chemical Reviews 118:4, pages 1599-1663.
Crossref
Crossref
Carmela Coppola, Anna Rienzo, Giovanna Piscopo, Antonio Barbieri, Claudio Arra & Nicola Maurea. (2018) Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs. Cancer Treatment Reviews 63, pages 135-143.
Crossref
Crossref
Mekonnen Sisay & Dumessa Edessa. (2017) PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers. Gynecologic Oncology Research and Practice 4:1.
Crossref
Crossref
Robert Cornelison, Danielle Llaneza & Charles Landen. (2017) Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review. International Journal of Molecular Sciences 18:10, pages 2171.
Crossref
Crossref
Luyao Wang, Chao Liang, Fangfei Li, Daogang Guan, Xiaoqiu Wu, Xuekun Fu, Aiping Lu & Ge Zhang. (2017) PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs. International Journal of Molecular Sciences 18:10, pages 2111.
Crossref
Crossref